Mesuximide
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]
References
- ↑ Pfizer AG (2005). “Petinutin (Mésuximide)”. Official Pfizer AG Website (in French). Retrieved August 21, 2006.
- ↑ Pfizer Inc. (2008). “Celontin (methsuximide capsules, USP)”. Official Pfizer Inc. Website. Retrieved November 21, 2014.
- ↑ Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH